[go: up one dir, main page]

IN2015DN03962A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03962A
IN2015DN03962A IN3962DEN2015A IN2015DN03962A IN 2015DN03962 A IN2015DN03962 A IN 2015DN03962A IN 3962DEN2015 A IN3962DEN2015 A IN 3962DEN2015A IN 2015DN03962 A IN2015DN03962 A IN 2015DN03962A
Authority
IN
India
Prior art keywords
mycobacterium
proteins
esx
secreted
tuberculosis
Prior art date
Application number
Inventor
Claus Aagaard
Ida Rosenkrands
Truc Thi Kim Thanh Hoang
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of IN2015DN03962A publication Critical patent/IN2015DN03962A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to fusion proteins antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria e.g. by Mycobacterium tuberculosis Mycobacterium africanum Mycobacterium bovis Mycobacterium microti Mycobacterium canettii Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT 6 secretion system 1 (ESX 1 ) which are among the most immunodominant M. tuberculosis (MTB) antigens.
IN3962DEN2015 2012-10-23 2013-10-18 IN2015DN03962A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201200654 2012-10-23
DKPA201200652 2012-10-23
DKPA201200653 2012-10-23
DKPA201300477 2013-08-23
PCT/DK2013/000070 WO2014063704A2 (en) 2012-10-23 2013-10-18 M. tuberculosis vaccines

Publications (1)

Publication Number Publication Date
IN2015DN03962A true IN2015DN03962A (en) 2015-10-02

Family

ID=49679267

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3962DEN2015 IN2015DN03962A (en) 2012-10-23 2013-10-18

Country Status (8)

Country Link
US (1) US9526773B2 (en)
EP (1) EP2912056B1 (en)
JP (1) JP6470179B2 (en)
CN (1) CN104736555B (en)
BR (1) BR112015009070A2 (en)
IN (1) IN2015DN03962A (en)
WO (1) WO2014063704A2 (en)
ZA (1) ZA201503467B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936131A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
AU2016333474A1 (en) 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
CN105218681B (en) * 2015-10-21 2019-06-25 中山大学 It is a kind of for induce peripheral blood mononuclear cells generate tuberculosis specific cytokines fusion protein
CN105218680B (en) * 2015-10-21 2019-06-25 中山大学 It is a kind of for induce peripheral blood mononuclear cells generate cell factor Mycobacterium tuberculosis fusion protein
CN105567660B (en) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 A kind of method and its application of Recombinant protein expression mycobacterium tuberculosis Rv2837c activated protein
JP2019521095A (en) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterial infections
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
US11958913B2 (en) * 2017-01-09 2024-04-16 Biomunex Pharmaceuticals Polypeptide linker for preparing multispecific antibodies
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
BR112021025172A2 (en) 2019-06-14 2022-01-25 Statens Seruminstitut Fusion proteins for tuberculosis vaccines
CN114423448A (en) * 2019-08-01 2022-04-29 塔夫茨大学信托人 Vaccine compositions and methods for selecting antigens
CN110590958B (en) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 Tandem polypeptide and application thereof in immune protection against mycobacterium tuberculosis
US20250170236A1 (en) 2022-02-21 2025-05-29 Statens Serum Institut A novel cationic adjuvant composition
CN115300618A (en) * 2022-05-11 2022-11-08 中国农业大学 Tuberculosis vaccine based on bovine beta defensin 5 and its application in preventing tuberculosis
CN115184603B (en) * 2022-06-30 2024-02-06 首都医科大学附属北京胸科医院 Application of EspC protein in preparation of mycobacterium tuberculosis separation or enrichment product
KR20250087737A (en) * 2023-12-06 2025-06-17 주식회사 미코라파 Tuberculosis vaccine composition comprising fusion protein inducing sterilizing immunity
CN118108815B (en) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 Mycobacterium tuberculosis multi-immunogen antigen, mRNA encoding same and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302870B6 (en) * 1998-04-07 2011-12-28 Corixa Corporation Polynucleotide, polypeptide, pharmaceutical composition, vaccine and their use for the treatment and prevention of tuberculosis infection
EP1914299B9 (en) 2002-04-05 2012-05-02 Institut Pasteur Identification of virulence associated region RD1 enabling the development of improved vaccines of M. microti
TR201903223T4 (en) * 2009-04-24 2019-03-21 Statens Seruminstitut A tuberculosis TB vaccine to prevent reactivation.
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Also Published As

Publication number Publication date
JP6470179B2 (en) 2019-02-13
US20150290311A1 (en) 2015-10-15
WO2014063704A8 (en) 2015-07-30
ZA201503467B (en) 2016-11-30
EP2912056B1 (en) 2020-02-12
BR112015009070A2 (en) 2017-07-04
WO2014063704A3 (en) 2014-06-19
WO2014063704A2 (en) 2014-05-01
JP2015536309A (en) 2015-12-21
US9526773B2 (en) 2016-12-27
EP2912056A2 (en) 2015-09-02
CN104736555A (en) 2015-06-24
CN104736555B (en) 2019-06-21

Similar Documents

Publication Publication Date Title
IN2015DN03962A (en)
BR112016023778A2 (en) antigen fusion or cocktail protein, use of an antigen fusion or cocktail protein, vaccine, and method for immunizing an animal, including a human, against tuberculosis caused by virulent mycobacteria
MX2016009072A (en) Fusion of heterooligomeric mycobacterial antigens.
EA201590184A1 (en) VACCINE ON THE BASIS OF MYCOBACTERIAL ANTIGENS
EA201990566A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
BR112018070187A2 (en) chimeric flt3 receptors and their methods of use
WO2013054199A3 (en) Cmv antigens and uses thereof
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
MX2022008079A (en) ANTIBODIES AGAINST SURFACE DETERMINANTS OF S. AUREUS.
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
MY191217A (en) Group a streptococcus vaccine
NZ717369A (en) Antibody titer-increasing agent using lactic acid bacterium
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
HK1254514A1 (en) Methods and compositions for enhancing immune response to vaccination
MX2018012270A (en) Novel pneumococcal vaccine formulations.
MX2019008779A (en) Pseudomonas antigens and antigen combinations.
EA201691091A1 (en) DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSTICS OF TUBERCULOSIS
WO2015184272A3 (en) Expression and conformational analysis of engineered influenza hemagglutinin
WO2014036438A3 (en) Live brucellosis vaccines comprising attenuated brucella mutants
WO2014160098A3 (en) Bordetella specific human recombinant antibodies and uses thereof
HK1214279A1 (en) Methods and compositions relating to anti-il-21 receptor antibodies
GB201120634D0 (en) Adjuvant polypeptide
WO2013093514A3 (en) Vaccines - peptides
WO2009023164A3 (en) Induction of mucosal immunity